Side-by-side · Research reference
PinealonvsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft12/36 cited
BPhase 2Reviewed10/41 cited
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
Pinealon
Retatrutide
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
Pinealon
Retatrutide
Standard dose
5–10 mg / day for 10 daysKhavinson 2014
12 mg / week (max efficacy)Jastreboff 2023
Phase 2 trial dose. Phase 3 dosing TBD.
Frequency
Once daily during cycle
Once weekly
Lower / starter dose
2.5 mg / day
—
Evidence basis
Russian clinical trials + in vitroKhavinson 2014
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
10-day cycles, 1–2× per year
Indefinite for chronic indication (presumed)
Reconstitution
Bacteriostatic water
Investigational; not commercially available
Timing
No specific time
Any time of day
Half-life
Hours
~6 days (estimated from class)
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
04Side Effects & Safety
Parameter
Pinealon
Retatrutide
Injection site reaction
Mild irritation
—
Long-term safety
Limited Western data
—
Pregnancy / OB
Avoid
Avoid (insufficient data)
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Absolute Contraindications
Pinealon
- ·Pregnancy / breastfeeding
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
Pinealon
Retatrutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Injection site
SQ — abdomen preferred.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Daily during cycle, any time.
Once weekly, same day.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C. Light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation
Retatrutide
— no documented stacks